ITCI

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-301.2M ExitQ2 2025 $301M -- $131.87
Paul Tudor Jones IITudor Investment $-82.0M ExitQ2 2025 $82M -- $131.87
George SorosSoros Fund Management $-15.4M ExitQ2 2025 $15M -- $131.87
John PaulsonPaulson & Co $-2.8M ExitQ2 2025 $3M -- $131.87
Jim SimonsRenaissance Technologies $-81.9M ExitQ2 2025 $82M -- $131.87
Jeremy GranthamGMO $-22.8M ExitQ2 2025 $23M -- $131.87

Congress Trades

Name	Value	Action	Amount Range	Price	Current Price
Josh GottheimerDemocrat $8k OtherApr 3, 2025 $1k-$15k -- $131.87
Gilbert CisnerosDemocrat $8k SellApr 3, 2025 $1k-$15k -- $131.87

Trade ITCI

About Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.

CEO: Sharon Mates
IPO Date: Jan 7, 2014

Market Data

Open: $131.87
High: $131.87
Low: $131.87
Volume: 16M
Avg Volume: 2.8M
52W High: $131.98
52W Low: $64.09

Valuation

Market Cap: $14B
Enterprise Value: $13.8B
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$73.5M
Revenue: $680.9M
Net Income: -$74.7M
Cash: $306.9M
Debt: $17M

Events

EarningsFeb 21

EPS est. -0.08 · actual -0.16